{"entity":{"id":"ubivac","kind":"company","name":"UbiVac","aka":[],"tldr":"UbiVac is developing an off-the-shelf cancer vaccine aimed at proteins made from non-coding regions of the genome, with RNA sequencing to check a patient's tumour expresses the targets, and early data in head and neck cancer.","summary":"UbiVac's vaccine targets proteins derived from non-coding genome regions that tumours express, screened per patient by RNA sequencing; Future of Cancer Care Today describes it as clinical-stage with good data in head and neck cancer, accessible through trial enrolment.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ubivac.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["ctgov-sponsor","fcct-directory"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"United States (city not published)","country":"US","companyType":"biotech","website":"https://www.ubivac.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/ubivac/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}]}}